Tipes
|
Kenymerk
|
Alternatiewe naam
|
Uitdruksstelsel
|
Aanwysing
|
Vervaardiger
|
Fase
|
FGF-1
|
Rekombinante menslike suur fibroblastgroeifaktor
|
艾夫吉夫, Suur FGF
|
Escherichia coli (E. coli)
|
Wondgenesing
|
Shanghai Tenry Pharmaceutical
|
Goedkeuring
|
FGF-1
|
Fibroblastgroeifaktor 1
|
CVBT-141, Suur FGF, Cardio Vascu-Grow
|
Wag opdate
|
Wondgenesing
|
Venturis Therapeutics, Inc.
|
Fase II
|
FGF-1
|
TTHX-1114
|
NM141
|
Wag opdate
|
Hoornvliesdystrofieë
|
Trefoil Therapeutics, Inc.
|
Fase II
|
FGF-1
|
Menslike Fibroblastgroei-factor 1
|
FGF-1
|
Wag opdate
|
Parkinsonse siekte
|
Zhittya Genesis Medicine, Inc.
|
Fase I
|
FGF-2
|
Rekombinante menslike basiese fibroblastgroei-factor
|
Gaifu, 盖扶
|
E. coli
|
Trauma en blessure, chirurgiese wonde
|
Langtide Biopharmaceutical
|
Goedkeuring
|
FGF-2
|
Rekombinante boeienbasiese fibroblast groeifaktor gel
|
贝复新
|
E. coli
|
Trauma en beserings
|
Zhuhai Essex Bio-Pharmaceutical
|
Goedkeuring
|
FGF-2
|
Trafermin
|
Fiblast Spray, CAB 2001, KCB-1, Regroth, KCB-1D, 曲弗明, リグロス
|
E. coli
|
Periodeontitis, Drukulsus, Huidulsus
|
Kaken Pharmaceutical Co., Ltd.
|
Goedkeuring
|
FGF-2
|
Trafermin biosoortig
|
Retympa, NPC 18, リティンパ | リティンパ耳科用250µgセット, Trafermin
|
Wag opdate
|
Tympaniese membran perforasie
|
Translational Research Informatics Center | Nobelpharma Co., Ltd.
|
Goedkeuring
|
FGF-2
|
Rekombinante boeien basisiese fibroblast groeifaktor
|
gesien bos
|
E. coli
|
Trauma en beserings
|
Changchun Changsheng Gene Pharmaceutical
|
Goedkeuring
|
FGF-2
|
Rekombinante basisiese fibroblast groeifaktor
|
help herstel
|
E. coli
|
Brandwonde
|
Beijing SL Pharmaceutical Co., Ltd.
|
Goedkeuring
|
FGF-2
|
Recombinante bovine basiese fibroblasgroeifaktor vir eksterne gebruik
|
贝复济
|
E. coli
|
Brandwonde, Huidulser
|
Zhuhai Essex Bio-Pharmaceutical
|
Goedkeuring
|
FGF-2
|
Rekombinante boeien basisiese fibroblast groeifaktor
|
贝复舒
|
E. coli
|
Hoornvliesulser, Hoornvliesontsteking, Brandwonde
|
Zhuhai Essex Bio-Pharmaceutical
|
Goedkeuring
|
FGF-2
|
Humane Fibroblasgroeifaktor 2
|
FGF-2
|
Wag opdate
|
Tympaniese membran perforasie
|
NYU Elaine A. & Kenneth G. Langone Medish Centrum
|
Fase II
|
FGF-2
|
Rekombinante boeien basisiese fibroblast groeifaktor
|
Wag opdate
|
Wag opdate
|
Stomatitis
|
Nanchang Universiteit
|
Fase II
|
FGF-2
|
Recombinante basiese fibroblasgroeifaktor
|
Wag opdate
|
Wag opdate
|
Trauma en beserings
|
China Gene PharmValley
|
Fase I
|
FGF-2
|
Rekombinante menslike fibroblastgroei-factor-2
|
rhFGF-2
|
Wag opdate
|
tandvlees terugtrekking
|
Universidade Federal Fluminense
|
Fase I
|
FGF-4
|
HST-001
|
Haarstimulerende kompleks, HSC-660, HST 001
|
Wag opdate
|
Haarverlies
|
Histogen, Inc.
|
Fase II
|
FGF-7
|
Palifermin
|
AMJ 9701, Kepivance
|
E. coli
|
Stomatitis
|
Swedish Orphan Biovitrum AB | Biovitrum AB
|
Goedkeuring
|
FGF-7
|
Palifermin biosimilar
|
Wag opdate
|
Wag opdate
|
Mukositis
|
Chengdu Zhitian Biological Engineering
|
Fase II
|
FGF-7
|
Rekombinante menslike keratinoïedgroeifaktor
|
Wag opdate
|
Wag opdate
|
In afwagting
|
Jiangsu Aosaikang Pharmaceutical
|
Fase I
|
FGF-19
|
Aldafermin
|
NGM-282, M-70, M52, rekombinante menslike FGF-19 variënt
|
E. coli
|
Fibrose, Nee-alkoholiese steatohepatitis, Tipe 2 suiker
|
NGM Biopharmaceuticals, Inc.
|
Fase II
|
FGF-21
|
Pegbelfermin
|
BMS 986036, ARX-618, PEG-FGF21, Pegylated FGF21, FGF-21 mimetiese proteïene
|
Wag opdate
|
Cirrose, Lewer siekte, Fibrose, Nee-alkoholiese steatohepatitis, Tipe 2 suiker
|
Bristol Myers Squibb Co., Ambrx, Inc.
|
Fase II
|
FGF-21
|
Efruxifermin
|
AKR-001, AMG-876, Fc-FGF21(RGE), EFX
|
Wag opdate
|
Cirrose, Nee-alkoholiese steatohepatitis, Tipe 2 Diabeetes
|
Akero Therapeutics, Inc.
|
Fase II
|
FGF-21
|
Fazpilodemab
|
BFKB 8488A, RG 7992, RO 7040551
|
Wag opdate
|
Nie-alkoholiese steatohepatitis, Siekte
|
Genentech, Inc.
|
Fase II
|
FGF-21
|
BOS-580
|
BOS 580, BOS-580-201, LLF 580, LLF-580
|
Wag opdate
|
Nie-alkoholiese steatohepatitis, Obesiteit
|
Boston Pharmaceuticals, Inc.
|
Fase II
|
FGF-21
|
NN-9499
|
NN9499, NNC 0194 0499
|
Wag opdate
|
Stofwisseling- en Voedingsversteuring, |Obesiteit
|
Novo Nordisk A/S
|
Fase II
|
FGF-21
|
Pegozafermin
|
BIO89 100, TEV 47948
|
Wag opdate
|
Swaar Hypertriglyceridemie NASH, Nie-alkoholiese Steatohepatitis
|
89bio, Inc.
|
Fase II
|
FGF-21
|
NGM-313
|
MK 3655
|
Wag opdate
|
Nie-alkoholiese steatohepatitis, Hepatitis, Obesiteit
|
Merck Sharp & Dohme Corp., Merck GmbH, Merck & Co., Inc., NGM Biopharmaceuticals, Inc., Werthenstein BioPharma GmbH
|
Fase II
|
FGF-21
|
Rekombinante pegylateerde menslike FGF21
|
B1344, PEG rekombinante menslike FGF21
|
Wag opdate
|
Tipe 2 diabetes, Nie-alkoholiese Steatohepatitis
|
Tasly Biopharmaceuticals Co., Ltd.
|
Fase I
|
FGF-21
|
DR10624
|
DR 10624
|
Wag opdate
|
Vetsoortige, Metaboliese Syndroom, Tipe 2 Diabetes
|
Zhejiang Doer Biologics Co., Ltd | Huadong Medicine Co., Ltd
|
Fase I
|
FGF-21
|
HEC-88473
|
HEC 88473
|
Wag opdate
|
Obesitas, Tipe 2 Diabetes, Nie-alkoholiese Vetlewer siekte, Vetlewer, Lewersiektes, Verdigestiewe Sistemiese Siektes
|
Dongguan HEC Biopharmaceutical R&D Co., Ltd., Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
|
Fase I
|
FGF-21
|
AP-026
|
AP 026
|
Wag opdate
|
Tipe 2 diabetes, Nie-alkoholiese Steatohepatitis
|
Ampsource Biopharma Shanghai Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
|
Fase I
|
FGF-21
|
Rekombinante FGF21-Fc fusionsieprotein
|
AP-025, langer werkende FGF-21 analog
|
Wag opdate
|
Nie-alkoholiese Steatohepatitis
|
Ampsource Biopharma Shanghai Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
|
Fase I
|
FGF-21
|
LY-3025876
|
Wag opdate
|
Wag opdate
|
Tipe 2 diabete
|
Eli Lilly & Co.
|
Fase I
|